Xori


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

XORI Corp. is a development stage company focused on a technology for the rapid discovery and development of therapeutic monoclonal antibodies for oncology, immune disorders and infectious disease.

XORI Corp. is a development stage company focused on a technology for the rapid discovery and development of therapeutic monoclonal antibodies for oncology, immune disorders and infectious disease.

Company (Alive / Active)

Phone:

Fax:

1616 Eastlake Ave. E.
Suite 205
Seattle, 98102
Washington, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Xori $2.1M May 22, 2009
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Xori Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 8 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Five Prime Therapeutics

South San Francisco, California, United States
IPO / Went publicFive Prime Therapeutics is a clinical-stage biotechnology company with a pipeline of antibodies and ligand traps for cancer, autoimmunity and respiratory diseases. FivePrime has differentiated discovery capabilities built on its library of secreted and extracellular human proteins, which it leverages in cell-based assays, in vivo models and receptor-ligand matching screens to identify medically relevant new targets and therapeutic proteins. FivePrime has entered into a collaboration agreement to...Show allLogin to see details

Sunesis Pharmaceuticals

South San Francisco, California, United States
IPO / Went publicSunesis is an oncology company developing cell-cycle inhibitors with a method of discovering drugs in pieces, or fragments. This Tethering is a process whereby the fragment is built out using the target protein's surface as a template to make a new full-size therapeutic compound. Per the company, they have developed collaborations with Biogen Idec, Johnson & Johnson PRD and Merck.Login to see details
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)